Circulating memory PD-1+CD8+ T cells and PD-1+CD8+T/PD-1+CD4+T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients
Jiang Liu, Degan Liu, Guangyin Hu, Jingjing Wang, Dadong Chen, Chuanjun Song, Yin Cai, Chentong Zhai, Wenjing Xu · 2023
Read Circulating memory PD-1+CD8+ T cells and PD-1+CD8+T/PD-1+CD4+T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients by Jiang Liu, Degan Liu, Guangyin Hu, Jingjing Wang, Dadong Chen, Chuanjun Song, Yin Cai, Chentong Zhai, Wenjing Xu (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10655311.txt.
Description
Liu and co-authors report a 2023 study on blood markers that may predict who benefits from immunotherapy for advanced stomach cancer. Only some patients respond to these drugs, so clinics need cheap tests to pick likely responders. The team focused on memory T cells in the blood that carry a marker called PD-1. They also tested a ratio between two T cell groups.
Records covered 187 patients treated at one hospital from December 2019 to February 2023. All got the same drug mix of immunotherapy plus standard chemotherapy. The authors used standard survival and outcome tests to set cut-off values for each marker. Their aim is a blood test that guides treatment choice before therapy starts.
Catalog record
| CREATOR | Jiang Liu, Degan Liu, Guangyin Hu, Jingjing Wang, Dadong Chen, Chuanjun Song, Yin Cai, Chentong Zhai, Wenjing Xu |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |